Menstrual bleeding: diagnosis and treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Heavy menstrual bleeding (HMB) is a common reason for women and adolescent girls to seek medical advice. This pathology increases maternal morbidity and mortality rates in pregnant women with existing anemia associated with heavy menstrual bleeding. The underestimation of the severity of this condition continues to be a pressing problem among clinicians and patients. HMB considerably worsens quality of life; therefore the purpose of therapy for this condition is to reduce menstrual blood loss, to normalize iron metabolic parameters, and to significantly improve quality of life.

Full Text

Restricted Access

About the authors

Elena N. Andreeva

National Medical Research Center of Endocrinology, Ministry of Health of Russia; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: endogin@mail.ru
MD, professor, deputy director of the center - director of the Institute of Reproductive Medicine; professor, Department of Reproductive Medicine and Surgery

Ekaterina V. Sheremetyeva

National Medical Research Center of Endocrinology, Ministry of Health of Russia

Email: sl98lk@yandex.ru
MD, endocrinologist, obstetrician-gynecologist at the Department of the Consultative and Diagnostic Center

References

  1. National Collaborating Centre for Women’s and Children’s Health. Heavy menstrual bleeding clinical guideline 44. London: RCOG Press for NICE; 2007.
  2. Bitzer J., Serrani M., Lahav A. Women’s attitudes towards heavy menstrual bleeding, and their impact on quality of life. Open Access J. Contraception. 2013; 4: 21-8.
  3. Palep-Singh M., Prentice A. Epidemiology of abnormal uterine bleeding. Best Pract. Res. Clin. Obstet. Gynaecol. 2007; 21(6): 887-90.
  4. Nance B.F., Delaney B., Dickson J.M. Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis. BMC Fam. Pract. 2018; 19(1): 135.
  5. Sriprasert I., Pakrashi T., Kimble T., Archer D.F. Heavy menstrual bleeding diagnosis and medical management. Contracept. Reprod. Med. 2017; 2: 20.
  6. Чернуха Г.Е., Ильина Л.М., Иванов И.А. Аномальные маточные кровотечения: ставим диагноз и выбираем лечение. Гинекология. 2018; 20(4): 4-8.
  7. Sasaki L.M.P., Andrade K.R.C., Figueiredo A.C.M.G., Wanderley M.D.S., Pereira M.G. Factors associated with malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and meta-analysis. J. Minim. Invasive Gynecol. 2018; 25(5): 777-85.
  8. Munro M.G., Critchley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int. J. Gynaecol. Obstet. 2018; 143(3): 393-408.
  9. Edelman A., Lew R., Cwiak C., Nichols M., Jensen J. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception. 2007; 75: 450-3.
  10. Андреева Е.Н. Обильные менструальные кровотечения: современный подход к проблеме и пути ее решения. Проблемы репродукции. 2015; 21(6): 39-47. doi: 10.17116 / repro201521639-47
  11. Fraser I.S., Langham S., Uhl-Hochgraeber K. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev. Obstet. Gynecol. 2009; 4(2): 179-89.
  12. Lam C., Anderson B., Lopes V., Schulkin J., Matteson K. Assessing abnormal uterine bleeding: are physicians taking a meaningful clinical history? J. Womens Health (Larchmt). 2017; 26 (7): 762-7.
  13. Heavy menstrual bleeding Guideline Development Group membership and acknowledgements. NICE: 2018.
  14. American College of Obstetricians and Gynecologists. Management of acute abnormal uterine bleeding in non-pregnant women. Committee Opinion №557. Obstet. Gynecol. 2013; 121(4): 891-6.
  15. Чернуха Г.Е., Немова Ю.И. Диагностика и медикаментозная терапия маточных кровотечений с позиций международных рекомендаций. Акушерство и гинекология: новости, мнения, обучение. 2013; 2: 12-7.
  16. Shabaan M.M., Zakherah M.S., El-Nashar S.A., Sayed G.H. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. Contraception. 2011; 83: 48-54.
  17. Sayed G.H., Zakherah M.S., El-Nashar S.A., Shaaban M.M. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fi broid-related menorrhagia. Int. J. Gynaecol. Obstet. 2011; 112: 126-30.
  18. Lukes A.S., Moore K.A., Muse K.N., Gersten J.K., Hecht B.R., Edlund M. et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet. Gynecol. 2010; 116(4): 865-75.
  19. Fraser I.S., Jensen J.T. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum. Reprod. 2011; 26(10): 2698-708.
  20. Jensen J.T., Parke S., Mellinger U. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet. Gynecol. 2011; 117 (4): 777-87.
  21. Актуальная инструкция по медицинскому применению препарата Клайра® № ЛП-000010 от 06.02.2019.
  22. Yu Q., Zhou Y., Suturina L., Jaisamrarn U., Lu D., Parke S. Efficacy and safety of estradiol valerate/dienogest for the management of heavy menstrual bleeding: a multicenter, double-blind, randomized, placebo-controlled, phase III clinical trial. J. Womens Health (Larchmt). 2018; 27(10): 1225-32.
  23. Briggs P., Serrani M., Vogtlander K., Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int. J. Womens Health. 2016; 8: 477-87.
  24. Всемирная Организация Здравоохранения. Медицинские критерии приемлемости использования методов контрацепции. 5-е изд. 2015.
  25. Nelson A., Parke S., Mellinger U., Zampaglione E., Schmidt A. Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America. J. Womens Health (Larchmt). 2014; 23(3): 204-10.
  26. Dinger J., Do Minh T., Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016; 94(4): 328-39.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies